Volition Validates Nu.Q NETs Biomarker In Sepsis; Stock Down

VolitionRx (VNRX) presented early-stage cancer detection data at ESMO MAP, showing 95% detection of stage I/II cancers using its Capture-Seq™ technology. The company targets a $36B market in early cancer detection and MRD, with plans to accelerate development and patent protection. Results showed no false positives in initial cohorts, with further studies underway.

VOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Friday, August 14 at 8:30 a.m. U.S. Eastern Time Henderson, Nevada, August 13, 2026 /PRNewswire/ -- Volit

VolitionRx Limited (NYSE American: VNRX) reported Q2 2026 revenue of about $0.4 million, flat versus Q2 2025, and first-half 2026 revenue of $1.4 million, up 112% year over year. Operating expenses fell 32% and operating loss was $4.2 million. The company said it is discussing licensing deals, including a Sysmex collaboration, and expects a $5 million milestone from a Nu.Q Vet feline assay peer review.

Nvidia (NVDA) and TCV invested in AI video startup Higgsfield, which has 40 million users and $1 billion annual revenue. The funding extends Higgsfield's Series B round, valued at $5.4 billion. Nvidia CEO Jensen Huang highlighted improvements in AI video systems, attributing advancements to agentic reasoning. Competition in AI video is growing, with rivals like Kling AI and Runway AI also raising significant funds.

Merck (MRK) CEO Rob Davis downplayed cost concerns over Intismeran, a personalized cancer vaccine developed with Moderna (MRNA). The drug, combined with Keytruda, reduced melanoma recurrence or death risk by 58% in six months. Merck and Moderna aim for approval by 2027. MRNA shares fell 17% after Phase 3 trial data was leaked, while MRK shares were down 2.2%.

TG Therapeutics (TGTX) reported Phase 1 trial results for azercabtagene zapreleucel in progressive MS patients. 89% of participants showed stable or improved EDSS scores at Day 90, with no high-grade toxicities observed. The study is ongoing with limited participants and short follow-up.